Newly reported from EULAR 2024: High Fatigue Rates Exist in Economically Disadvantaged Patients with RA
Newly reported from EULAR 2024: High Fatigue Rates Exist in Economically Disadvantaged Patients with RA A recent study highlighted the substantial prevalence of severe fatigue among poor patients with rheumatoid arthritis (RA). Investigators presented the data at the 2024 European Alliance of Associations for Rheumatology (EULAR) from June 12 – 15, in Vienna, Austria. “Younger age, smoking, […]
News Coverage from EULAR 2024: Higher Fertility Rates Observed in Male Patients with Rheumatic Disease
News Coverage from EULAR 2024: Higher Fertility Rates Observed in Male Patients with Rheumatic Disease Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA) have a higher number of children per man and are less likely to be childless compared with a cohort of controls from the general population, according to data from a large, […]
Reporting from EULAR 2024: Adalimumab Biosimilar MSB11022 Demonstrates Comparable Safety, Efficacy in RA
Reporting from EULAR 2024: Adalimumab Biosimilar MSB11022 Demonstrates Comparable Safety, Efficacy in RA Among patients with rheumatoid arthritis (RA), treatment with the adalimumab biosimilar MSB11022 was shown to sustain the prior benefits reported in previous adalimumab treatment, according to data presented at the 2024 European Congress of Rheumatology (EULAR). In some cases, treatment with the biosimilar led to greater improvements […]
Broadcasting from EULAR 2024: Dazodalibep Significantly Improves Disease Activity in Rheumatoid Arthritis
Broadcasting from EULAR 2024: Dazodalibep Significantly Improves Disease Activity in Rheumatoid Arthritis Dazodalibep significantly improves disease activity and swollen and tender joint counts in patients with moderate-to-severe active rheumatoid arthritis (RA), according to new findings from the Phase 2 MIDORA clinical trial. The drug, a non-antibody fusion protein that targets CD40L, also reduced biomarkers of T- […]
Directly from EULAR 2024: Study Reveals Romosozumab, Denosumab Effectively Treats RA Complicated with Osteoporosis
Directly from EULAR 2024: Study Reveals Romosozumab, Denosumab Effectively Treats RA Complicated with Osteoporosis Treatment with romosozumab or denosumab among patients with either primary osteoporosis or rheumatoid arthritis (RA) complicated with osteoporosis (RA-OP) demonstrated clinical efficacy over separate 12-month treatment periods, according to a prospective cohort study presented at the 2024 European Congress of Rheumatology (EULAR). Investigators believe these […]
Newly reported from EULAR 2024: Higher Step Count Lowers Risk of Developing RA by 45%
Newly reported from EULAR 2024: Higher Step Count Lowers Risk of Developing RA by 45% A higher daily step count was linked to a lower risk of developing rheumatoid arthritis (RA), according to a prospective cohort study presented at the 2024 European Congress of Rheumatology (EULAR). The benefits of incremental increases (1000 steps per day) were particularly notable […]
Newscasting from EULAR 2024: Analysis Demonstrates Long-Term Safety Profile of Filgotinib for RA Treatment
Newscasting from EULAR 2024: Analysis Demonstrates Long-Term Safety Profile of Filgotinib for RA Treatment The safety profile of filgotinib remained stable more than 4 years among a cohort of patients with moderate to severe rheumatoid arthritis (RA), according to an updated integrated safety analysis presented at the 2024 European Congress of Rheumatology (EULAR). These results were comparable to […]
Broadcasting from EULAR 2024: Illness Perception Linked to Subjective Signs of RA Disease Activity
Broadcasting from EULAR 2024: Illness Perception Linked to Subjective Signs of RA Disease Activity Illness perception, anxiety, and depression are linked to subjective signs of disease activity in rheumatoid arthritis (RA), a study found. The data was presented as an abstract, led by Irina Gessl, MD, from the Medical University of Vienna, at the 2024 European Alliance […]
News Coverage from EULAR 2024: Abiprubart Reduces Disease Activity in Refractory Rheumatoid Arthritis
News Coverage from EULAR 2024: Abiprubart Reduces Disease Activity in Refractory Rheumatoid Arthritis Abiprubart (KPL-404) demonstrated improvements in disease activity in patients with refractory rheumatoid arthritis (RA), compared with placebo, according to new Phase 2 data presented at the 2024 European Congress of Rheumatology (EULAR). These findings showed statistically significant reduction in the Disease Activity Score […]
Directly from EULAR 2024: 8 out of 10 Patients with RA Achieve Sustained Remission at Month 12 with Upadacitinib
Directly from EULAR 2024: 8 out of 10 Patients with RA Achieve Sustained Remission at Month 12 with Upadacitinib In real-world practice, >79% of patients with moderate to severe rheumatoid arthritis (RA)were able to achieve Disease Activity Score-28 for Rheumatoid Arthritis with C-reactive protein (DAS28-CRP) remission by 6 months, which was maintained through month 12, according […]
